文献速递乳腺癌

男性乳腺癌风险与非BRCA1/2基因致病性变异相关:一项意大利病例对照研究

Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study.
PubMed 文献 · Eur J Cancer · 2023-05-02

该意大利病例对照研究纳入767例BRCA1/2阴性男性乳腺癌和1349例男性对照,用50基因面板筛查,发现非BRCA1/2基因致病性变异在病例组更常见(4.8% vs 1.8%),与男性乳腺癌风险约三倍升高相关(OR 3.48),PALB2和ATM变异分别与约七倍和约五倍风险升高相关。

要点

  • 非BRCA1/2基因致病性变异在男性乳腺癌中占4.8%,对照中占1.8%,OR 3.48(95%CI 1.88-6.44)。
  • PALB2致病性变异与男性乳腺癌风险约七倍升高相关(OR 7.28,95%CI 1.17-45.52)。
  • ATM致病性变异与男性乳腺癌风险约五倍升高相关(OR 4.79,95%CI 1.12-20.56)。

核心结论

  • 本研究凸显PALB2和ATM致病性变异在男性乳腺癌易感性中的作用,并提供人群水平风险估计。
  • 这些数据可能有助于在男性乳腺癌患者中实施多基因面板检测,并为患者及家庭提供性别特异性乳腺癌风险管理与决策信息。

研究设计与样本

  • 在意大利人群中开展的大规模病例对照研究,纳入767例BRCA1/2阴性男性乳腺癌和1349例男性对照。
  • 所有受试者均使用定制的50癌症基因面板进行筛查。

主要发现

  • 非BRCA1/2基因致病性变异在男性乳腺癌中显著更常见:病例组4.8% vs 对照组1.8%,与男性乳腺癌风险约三倍升高相关(OR 3.48,95%CI 1.88-6.44;p < 0.0001)。
  • 携带致病性变异者更可能有个人癌症史(p = 0.03)和家族癌症史(p = 0.02),不限于乳腺癌。
  • PALB2致病性变异与男性乳腺癌风险约七倍升高相关(OR 7.28,95%CI 1.17-45.52;p = 0.034)。
  • ATM致病性变异与男性乳腺癌风险约五倍升高相关(OR 4.79,95%CI 1.12-20.56;p = 0.035)。

临床怎么用

  • 作者认为这些数据可能有助于在男性乳腺癌患者中实施多基因面板检测,并为患者及家庭提供性别特异性乳腺癌风险管理与决策信息。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Germline pathogenic variants (PVs) in BRCA1/2 genes are associated with breast cancer (BC) risk in both women and men. Multigene panel testing is being increasingly used for BC risk assessment, allowing the identification of PVs in genes other than BRCA1/2. While data on actionable PVs in other cancer susceptibility genes are now available in female BC, reliable data are still lacking in male BC (MBC). This study aimed to provide the patterns, prevalence and risk estimates associated with PVs in non-BRCA1/2 genes for MBC in order to improve BC prevention for male patients. METHODS: We performed a large case-control study in the Italian population, including 767 BRCA1/2-negative MBCs and 1349 male controls, all screened using a custom 50 cancer gene panel. RESULTS: PVs in genes other than BRCA1/2 were significantly more frequent in MBCs compared with controls (4.8% vs 1.8%, respectively) and associated with a threefold increased MBC risk (OR: 3.48, 95% CI: 1.88-6.44; p < 0.0001). PV carriers were more likely to have personal (p = 0.03) and family (p = 0.02) history of cancers, not limited to BC. PALB2 PVs were associated with a sevenfold increased MBC risk (OR: 7.28, 95% CI: 1.17-45.52; p = 0.034), and ATM PVs with a fivefold increased MBC risk (OR: 4.79, 95% CI: 1.12-20.56; p = 0.035). CONCLUSIONS: This study highlights the role of PALB2 and ATM PVs in MBC susceptibility and provides risk estimates at population level. These data may help in the implementation of multigene panel testing in MBC patients and inform gender-specific BC risk management and decision making for patients and their families.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Bucalo A, Conti G, Valentini V, et al. Male breast cancer risk associated with pathogenic variants in genes other than BRCA1/2: an Italian case-control study. Eur J Cancer. 2023. PMID: 37262986. doi:10.1016/j.ejca.2023.04.022

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。